Description

Tranexamic Acid Injection

Healthy Inc is a specialized global supplier and exporter of critical care and life-saving hemostatic therapies. We provide high-purity Tranexamic Acid Injection (100 mg/ml), manufactured in WHO–GMP certified sterile facilities. This “Antifibrinolytic” specialist is a mandatory export to trauma centers, maternity wards, surgical suites, and government health ministries in Africa, LATAM, and Southeast Asia, serving as the definitive frontline intervention for preventing and treating severe hemorrhage, particularly in trauma and postpartum scenarios.

Product Overview

This formulation contains Tranexamic Acid (TXA), a synthetic derivative of the amino acid lysine that acts as a potent antifibrinolytic agent.

The “Fibrin Preserver” Specialist:

• Mechanism (Plasminogen Blockade): The body naturally dissolves blood clots through a process called fibrinolysis, driven by the enzyme plasmin. Tranexamic Acid competitively and reversibly binds to the lysine receptor sites on plasminogen. This prevents plasminogen from converting into active plasmin, thereby stopping the premature degradation of the fibrin matrix and stabilizing the blood clot until tissue repair is complete.
• Trauma & Emergency Utility: In acute severe trauma with massive bleeding, early administration of IV TXA (within 3 hours of injury) significantly reduces mortality by preventing the rapid breakdown of life-saving clots.
• Maternal Health Standard: It is the global WHO-recommended standard of care for the treatment of severe Postpartum Hemorrhage (PPH), a leading cause of maternal mortality in developing nations.

Product Composition & Strength

We supply this product as a Sterile, Clear, Colorless Aqueous Solution in glass ampoules.

*Pack Sizes: Tray of 5 or 10 Ampoules.

Technical & Logistics Specifications

Critical data for Pharmaceutical Importers and Distributors.

Manufacturing Authority

Marketed and Distributed by Healthy Inc from WHO-GMP & ISO 9001:2015 certified units.

• pH Stability: Formulated within a precise pH range (6.5 to 8.0) to maintain molecular stability and prevent precipitation, ensuring it can be safely mixed with most common infusion fluids (like 0.9% Normal Saline or 5% Dextrose) during emergency protocols.
• Terminal Sterilization: The filled ampoules are terminally sterilized via autoclaving to guarantee a 100% pyrogen-free product, essential for massive IV transfusions during critical hemorrhagic shock.

Therapeutic Indications (Human Use)

Indicated for the prevention and treatment of hemorrhage due to general or local fibrinolysis:

• Postpartum Hemorrhage (PPH): Treatment of massive bleeding following childbirth.
• Acute Trauma: Management of severe hemorrhagic shock in accident victims.
• Surgical Bleeding: Prostatectomy, cardiac surgery, cervical conization, and major orthopedic procedures (e.g., knee/hip arthroplasty).
• Dental Extractions: Prevention of bleeding in patients with hemophilia or those on anticoagulant therapy.

Dosage & Administration

Recommended Dosage (Strictly as per Physician):

• Route: Slow Intravenous (IV) Injection or Continuous IV Infusion.
• CRITICAL WARNING (Administration Rate): DO NOT INJECT RAPIDLY. Rapid IV injection can cause severe, sudden hypotension (drop in blood pressure). The maximum injection rate is 1 ml/minute (100 mg/minute).
• Standard Adult Dose (General Fibrinolysis): 1000 mg (1 g) by slow IV injection, repeated every 6 to 8 hours as necessary.
• Trauma Protocol: 1 g loading dose infused over 10 minutes, followed by an IV infusion of 1 g over the next 8 hours.
• Renal Impairment: Because TXA is excreted unchanged in the urine, dosages must be drastically reduced in patients with renal failure to prevent toxic accumulation.

Safety Warnings (CRITICAL):

• Thrombotic Risk: Contraindicated in patients with active intravascular clotting conditions (like Deep Vein Thrombosis, Pulmonary Embolism) or a history of thromboembolic disease, as it can propagate fatal blood clots.
• Disseminated Intravascular Coagulation (DIC): Should not be used in DIC unless the condition is predominantly caused by an overactive fibrinolytic state.
• Seizures: High doses, especially during cardiac surgery or accidental intrathecal/epidural administration, have been associated with severe post-operative seizures.
• Visual Disturbances: Patients on prolonged therapy should undergo regular ophthalmic examinations, as TXA can occasionally cause changes in color vision and retinal architecture.

Global Export & Contract Manufacturing Services

Healthy Inc stands as a premier Pharmaceutical Exporter in India, dedicated to serving the needs of international Pharma Traders, Wholesalers, and Bulk Drug Distributors. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) services for Critical Care Injectables, allowing brands to launch high-quality generic medicines under their own label. Whether you are looking for a reliable Hospital Tender Supplier for government procurement in Africa or a B2B Pharma Marketplace partner for Latin America, our logistics network ensures timely delivery. We actively support Pharmaceutical Drop Shipping models and bulk indenting, ensuring that every Generic Medicine Wholesaler receives WHO-GMP certified products at competitive rates.